The state of Texas currently has 100 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
NCT05955339
Recruiting
CHRONICLE is a randomized trial assessing the comparative effectiveness of providing written visit information via the patient portal (NOTES) versus NOTES plus visit audio recording (AUDIO) to older adult patients with chronic diseases on quality of life and other outcomes. During the trial, the team will also invite caregivers identified by patients to join the project.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Diabetes Mellitus, Hypertension
Register for Updates
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
NCT06192108
Recruiting
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/18/2024
Locations: Dallas Diabetes Research Center, Dallas, Texas +2 locations
Conditions: Type 2 Diabetes
Register for Updates
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
NCT05514535
Recruiting
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide together with a lower dose of insulin glargine or a higher dose of insulin glargine. The study will last for about 47 weeks (approximately 11 months). Participants will have 9 clinic visits, 15 phone/video calls and 1 home vi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/17/2024
Locations: Amarillo Med Spec LLP, Amarillo, Texas +11 locations
Conditions: Diabetes Mellitus, Type 2, Obesity
Register for Updates
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
NCT03929601
Recruiting
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to a 2-hour mixed meal tolerance test, will be improved in participants with new onset T1D who are treated with Abatacept after Rituximab-pvvr compared to those treated with Rituximab-pvvr and placebo 24 months after enrollment.
Gender:
All
Ages:
Between 8 years and 45 years
Trial Updated:
03/13/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Type 1 Diabetes Mellitus
Register for Updates
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Texas Diabetes & Endocrinology, P.A., Austin, Texas +26 locations
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
Register for Updates
Polypill for Prevention of Cardiomyopathy
NCT06143566
Recruiting
This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 50 or 100 mg, and finerenone 10 mg daily. The study duration is 3 months, and participants will be randomized to either polypill therapy or usual care. The primary outcome is change in peak VO2 and adherence to usual care. The investigators hypo... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/11/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Type 2 Diabetes, High Blood Pressure
Register for Updates
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
NCT06152042
Recruiting
Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
03/04/2024
Locations: PlanIt Research, PLLC, Houston, Texas +4 locations
Conditions: Type 1 Diabetes Mellitus
Register for Updates
Immune Function and the Progression to T1D
NCT05899439
Recruiting
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.
Gender:
All
Ages:
Between 0 years and 100 years
Trial Updated:
02/27/2024
Locations: Baylor College of Medicine, Center for Research Advancement - Texas Children's Hospital, Houston, Texas
Conditions: Type 1 Diabetes
Register for Updates
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
NCT05772169
Recruiting
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%) despite receiving standard-of-care therapies. Part 2 (Treatment Phase) is a randomized, prospective, placebo-controlled, double-blind multi-center trial that will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult to... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/22/2024
Locations: Site 456, Cedar Park, Texas +4 locations
Conditions: Hypercortisolism, Diabetes Mellitus, Type 2
Register for Updates
In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
NCT05238142
Recruiting
The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes in a home setting. The combined run-in period and study period will be approximately 135 days long.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
02/15/2024
Locations: Texas Diabetes and Endocrinology, Austin, Texas +5 locations
Conditions: Type 2 Diabetes Treated With Insulin
Register for Updates
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
NCT05743244
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
02/14/2024
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Ketones, SGLT2, HFrEF
NCT06229678
Recruiting
The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an energy-rich fuel that is taken up with great avidity by the myocardium, to measure change in Left Ventricle diastolic and systolic function
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
02/13/2024
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas
Conditions: Type2diabetes, Heart Failure With Reduced Ejection Fraction
Register for Updates